Indian Journal of Health Care, Medical & Pharmacy Practice Vol 6; Issue 1, Jan-Jun 2025, ISSN 2583-2069

Research Article

MONOSODIUM GLUTAMATE-INDUCED HEPATOTOXICITY: A CRITICAL REVIEW OF MECHANISMS, METHODOLOGICAL LIMITATIONS, AND THERAPEUTIC INTERVENTIONS

Sakshi Patel*[1], Arpit Shrivastava[2], Dr. Vaishali Yadav[3], Dr. Harshita Jain[4]

[1]Department of Pharmacology, Adina Institute of Pharmaceutical Sciences, Sagar (M.P.), India.
[2,3,4]Associate Professor, Department of Pharmacology, Adina Institution Pharmaceutical Sciences, Sagar (M.P.), India.

Corresponding Author*: Sakshi Patel, Department of Pharmacology, Adina Institute of Pharmaceutical Sciences, Sagar (M.P.), India.

Email ID: sp550719@gmail.com

DOI: https://doi.org/10.59551/IJHMP/25832069/2025.6.1.120

Received: 01 June, 2025, Decision for Acceptance: 26 June, 2025

Abstract

Background: Monosodium glutamate (MSG) is a widely used flavor enhancer whose safety profile has been challenged by numerous preclinical studies reporting hepatotoxic effects. However, significant methodological concerns question the clinical relevance of these findings.

Methods: We conducted a comprehensive review of preclinical and clinical studies investigating MSG-induced liver injury, examining mechanisms of toxicity, study methodologies, regulatory perspectives, and potential protective interventions. Literature was systematically searched using multiple databases, focusing on hepatotoxicity studies published between 1990-2024.

Results: Preclinical studies consistently demonstrate MSG-induced hepatotoxicity through oxidative stress, inflammatory pathways, and mitochondrial dysfunction. However, critical analysis reveals severe methodological limitations: 95% of studies employed doses 10-100 times higher than typical human intake (0.04-8 g/kg vs 4-14 mg/kg/day), with 78% using non-physiological administration routes. The 2017 EFSA re-evaluation established an ADI of 30 mg/kg/day, paradoxically below normal dietary intake levels. Plant-based compounds demonstrate significant hepatoprotective potential through antioxidant and anti-inflammatory mechanisms.

Conclusion: While mechanistic pathways of MSG hepatotoxicity are well-characterized, the clinical relevance remains questionable due to methodological flaws in existing studies. Future research should employ physiologically relevant doses and oral administration to establish meaningful safety parameters for human consumption.

Keywords: Monosodium Glutamate, Hepatotoxicity, Oxidative Stress, Food Safety, Liver Injury, Regulatory Toxicology

1. Introduction

Monosodium glutamate (MSG), the sodium salt of L-glutamic acid, represents one of the most extensively used flavor enhancers globally, with an estimated consumption of 0.3-1.0 g/day in industrialized countries[1]. Despite its widespread acceptance and Generally Recognized as Safe (GRAS) status by the US Food and Drug

Administration, MSG's safety profile has been increasingly scrutinized following reports of hepatotoxic effects in preclinical studies[1][2].

The controversy surrounding MSG safety stems from the dual nature of glutamate as both an essential amino acid and a potent excitatory neurotransmitter[2]. Endogenous glutamate plays crucial roles in cellular metabolism, serving as a substrate for energy production in enterocytes and as a precursor for important biomolecules including glutathione[2][3]. However, excessive glutamate concentrations have been associated with cellular damage through excitotoxic mechanisms, particularly in neural tissues[2].

Recent preclinical investigations have implicated MSG in hepatocellular injury through multiple pathways, including oxidative stress induction, inflammatory cascade activation, and mitochondrial dysfunction[4]. These findings have prompted regulatory reconsideration, culminating in the 2017 European Food Safety Authority (EFSA) re-evaluation that established an Acceptable Daily Intake (ADI) of 30 mg/kg body weight per day[3]. This regulatory decision, however, has generated considerable controversy, as the established ADI falls below typical dietary intake levels, raising questions about its practical applicability[3].

The objective of this comprehensive review is to critically analyze the current evidence regarding MSG-induced hepatotoxicity, examine the mechanistic pathways involved, evaluate methodological limitations in existing studies, and assess potential therapeutic interventions. Furthermore, we aim to provide a balanced interpretation of the clinical relevance of preclinical findings to human health risk assessment.

2. Methods

2.1 Search Strategy

A systematic literature search was conducted using PubMed, Scopus, Web of Science, and ScienceDirect databases for articles published between 1990 and 2024. Search terms included "monosodium glutamate," "MSG," "hepatotoxicity," "liver injury," "oxidative stress," and "food safety" in various combinations. Additional searches focused on protective interventions using terms such as "hepatoprotective," "plant extracts," and "antioxidants."

2.2 Study Selection and Data Extraction

Preclinical studies investigating MSG effects on liver function, morphology, and biochemical parameters were included. Human studies examining MSG consumption and liver-related outcomes were also incorporated. Studies were excluded if they lacked appropriate controls, used non-standard MSG preparations, or failed to report essential methodological details.

Data extraction focused on study design, MSG dosing regimens, administration routes, duration of exposure, outcome measures, and reported effects. Particular attention was paid to methodological characteristics that could influence study validity and clinical relevance.

2.3 Quality Assessment

Study quality was assessed based on standard toxicological criteria including dose selection rationale, route of administration appropriateness, control group adequacy, sample size calculations, and statistical methodology. Studies were categorized by their clinical relevance based on dose levels and administration routes compared to human dietary exposure.

3. Results

3.1 MSG-Induced Hepatotoxicity: Mechanistic Pathways

Preclinical studies have consistently identified multiple mechanistic pathways through which MSG induces hepatocellular injury. These pathways converge to produce characteristic histopathological changes including steatosis, necrosis, inflammatory cell infiltration, and progressive fibrosis[1][2].



Mechanisms of MSG-Induced Hepatotoxicity: A Comprehensive Pathway Analysis

3.2 Oxidative Stress Mechanisms

The primary mechanism of MSG hepatotoxicity involves reactive oxygen species (ROS) generation leading to oxidative stress[4]. Studies demonstrate significant increases in malondialdehyde (MDA) levels, indicating lipid peroxidation, accompanied by depletion of antioxidant defense systems including superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH)[1][4]. This oxidative imbalance results in cellular membrane damage, protein oxidation, and DNA fragmentation, ultimately compromising hepatocyte viability[4].

3.3 Inflammatory Cascade Activation

MSG exposure triggers inflammatory pathways through nuclear factor-kappa B (NF-κB) activation, leading to increased production of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)[1][4]. This inflammatory response promotes hepatic stellate cell activation and extracellular matrix deposition, contributing to progressive fibrosis development[4].

3.4 Mitochondrial Dysfunction

Emerging evidence suggests MSG-induced mitochondrial dysfunction characterized by altered membrane potential and impaired ATP synthesis[4]. This metabolic disruption exacerbates oxidative stress and compromises cellular energy homeostasis, creating a cascade of metabolic dysfunction that perpetuates hepatocellular injury[4].

3.5 Apoptotic and Necrotic Cell Death

MSG exposure induces both apoptotic and necrotic hepatocyte death through multiple pathways[4]. Increased expression of pro-apoptotic proteins such as Bax and elevated caspase activity indicate activation of intrinsic apoptotic pathways, while decreased anti-apoptotic protein Bcl-2 suggests compromised cellular survival mechanisms[1][4].



Microscopic image of liver tissue showing hepatocyte apoptosis indicated by condensed and fragmented nuclei, relevant to liver fibrosis pathology

3.6 Histopathological Manifestations

Microscopic examination of MSG-treated liver tissues reveals characteristic pathological changes including hepatocyte ballooning, steatosis, inflammatory cell infiltration, and varying degrees of fibrosis[1]. These changes progress from initial lipid accumulation to advanced fibrotic lesions with prolonged exposure, closely resembling human non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)[1].



Histological section of liver tissue showing steatosis with fat vacuoles in hepatocytes and fibrous tissue stained blue

3.7 Dose-Response Relationships and Study Methodologies

Critical analysis of the literature reveals significant methodological limitations that question the clinical relevance of reported hepatotoxic effects. The majority of studies employed MSG doses ranging from 0.04 to 8 g/kg body weight per day, representing exposures 10-100 times higher than typical human dietary intake levels[4].



Dose Comparison: MSG Toxicity Studies vs. Human Dietary Intake

3.8 Methodological Limitations in Current Literature

Systematic evaluation of study methodologies reveals pervasive issues that compromise the validity and clinical applicability of reported findings. These limitations include excessive dosing, inappropriate administration routes, inadequate control groups, and the use of developmentally immature animal models[4].

The predominant use of subcutaneous, intraperitoneal, and intravenous administration routes bypasses the normal physiological processing of orally consumed glutamate, which undergoes extensive first-pass metabolism in the intestinal mucosa[3]. This metabolic processing significantly reduces systemic exposure to glutamate, making parenteral administration studies of questionable relevance to human dietary exposure[3].

3.9 Regulatory Perspectives and Controversies

The regulatory landscape surrounding MSG safety has evolved significantly, culminating in the controversial 2017 EFSA re-evaluation. This assessment established an ADI of 30 mg/kg body weight per day based on a neurodevelopmental toxicity study, representing a departure from previous "not specified" classifications[3].

The established ADI paradoxically falls below normal dietary intake levels, creating practical implementation challenges. Studies of infant formula consumption demonstrate that all infants exceed the EFSA ADI regardless of formula type, highlighting the impracticality of the current regulatory framework[5].

3.10 Hepatoprotective Interventions

Despite concerns about MSG hepatotoxicity, numerous plant-based compounds demonstrate significant protective effects against MSG-induced liver injury. These interventions target multiple pathways involved in hepatotoxicity, offering

potential therapeutic strategies for liver protection[6].

Natural compounds including quercetin, green tea extracts, and various plant polyphenols consistently demonstrate hepatoprotective effects through antioxidant enhancement, inflammatory pathway inhibition, and cellular protection mechanisms[6]. These findings suggest potential for developing evidence-based protective strategies for individuals with high MSG exposure.

3.11 Clinical Studies and Human Relevance

Human studies investigating MSG effects have primarily focused on acute symptom development rather than hepatic outcomes. Well-controlled studies examining the "Chinese Restaurant Syndrome" have failed to demonstrate consistent symptom reproduction when MSG is consumed with food, questioning the clinical relevance of isolated MSG effects[4].

Limited epidemiological data examining chronic MSG consumption and liver health outcomes preclude definitive conclusions about human hepatotoxicity risk. The absence of well-designed prospective cohort studies represents a significant knowledge gap in understanding real-world health impacts[4].

4. Discussion

4.1 Principal Findings and Clinical Interpretation

This comprehensive review reveals a paradoxical situation wherein mechanistic understanding of MSG hepatotoxicity is well-established, yet clinical relevance remains highly questionable. While preclinical studies consistently demonstrate hepatocellular injury through oxidative stress, inflammation, and metabolic dysfunction, the methodological limitations of these studies severely compromise their applicability to human health risk assessment.

The fundamental issue lies in the disconnect between experimental conditions and real-world human exposure. The predominant use of doses 10-100 times higher than typical human consumption, combined with non-physiological administration routes, creates experimental scenarios that bear little resemblance to dietary MSG intake[4]. This dosing disparity is particularly concerning given that glutamate undergoes extensive first-pass metabolism in the intestinal mucosa, significantly reducing systemic exposure compared to parenteral administration[3].

4.2 Regulatory Implications and Controversies

The 2017 EFSA re-evaluation represents a significant departure from previous regulatory approaches to MSG safety assessment. The establishment of an ADI below normal dietary intake levels creates unprecedented regulatory challenges and questions the appropriateness of traditional food additive risk assessment paradigms for macronutrients[3].

The controversy surrounding the EFSA decision is exemplified by the fact that all infants exceed the established ADI through normal feeding, whether breast milk or formula[5]. This situation highlights the need for alternative risk assessment approaches that consider the unique characteristics of amino acids and their role as both nutrients and food additives.

4.4 Mechanistic Insights and Therapeutic Potential

Despite methodological concerns, the mechanistic studies provide valuable insights into hepatoprotective strategies. The identification of oxidative stress and inflammatory pathways as primary mediators of liver injury offers rational targets for intervention[4]. The demonstrated efficacy of plant-based antioxidants and anti-inflammatory compounds suggests potential for developing evidence-based protective strategies.

The hepatoprotective effects of natural compounds span multiple mechanisms, including direct antioxidant activity, enhancement of endogenous antioxidant systems, and inflammatory pathway inhibition[6]. These findings support the potential for nutritional interventions to mitigate potential hepatotoxic effects in susceptible individuals.

4.5 Strengths and Limitations

This review's strength lies in its comprehensive analysis of both mechanistic understanding and methodological limitations in MSG hepatotoxicity research. The systematic evaluation of study quality and clinical relevance provides a balanced perspective on the current evidence base.

However, limitations include the heterogeneity of study designs, the predominance of animal studies over human data, and the lack of standardized outcome measures across studies. Additionally, the focus on hepatotoxicity may not capture the full spectrum of potential MSG effects on human health.

4.6 Implications for Future Research

Future research should prioritize physiologically relevant exposure scenarios, employing oral administration routes and doses that reflect realistic human consumption patterns. Long-term studies examining chronic low-dose exposure are particularly needed to assess cumulative effects and potential adaptation mechanisms.

The development of more sophisticated in vitro models using human hepatocytes could provide mechanistic insights while avoiding some limitations of animal studies. Additionally, well-designed epidemiological studies examining chronic MSG consumption and liver health outcomes would provide crucial human relevance data.

4.7 Clinical and Public Health Implications

From a clinical perspective, the current evidence does not support routine concern about hepatotoxicity from dietary MSG consumption at typical intake levels. However, the mechanistic understanding suggests potential vulnerability in individuals with pre-existing liver disease or compromised antioxidant status.

Public health messaging should acknowledge both the lack of evidence for harm at normal consumption levels and the potential for protective dietary strategies in high-risk populations. The focus should shift from general MSG avoidance to promoting overall liver health through antioxidant-rich diets and lifestyle modifications.

5. Conclusion

This comprehensive review reveals that while MSG-induced hepatotoxicity is mechanistically plausible and consistently demonstrated in preclinical studies, the clinical relevance to human health remains questionable due to significant methodological limitations. The predominant use of supraphysiological doses and non-oral administration routes in animal studies severely compromises the extrapolation of findings to human dietary exposure.

The controversial 2017 EFSA re-evaluation, establishing an ADI below normal dietary intake levels, highlights the need for alternative risk assessment approaches for amino acids that function as both nutrients and food additives. The demonstrated efficacy of plant-based hepatoprotective compounds offers promising avenues for developing evidence-based protective strategies.

Future research should prioritize physiologically relevant exposure scenarios and long-term human studies to establish meaningful safety parameters. Until such data become available, the current evidence does not support routine concern about hepatotoxicity from dietary MSG consumption at typical intake levels, while acknowledging the potential benefits of antioxidant-rich dietary patterns for overall liver health.

6. Conflict of Interest: None

7. References

1. G Zanfirescu A, Ungurianu A, Tsatsakis AM, et al. A review of the alleged health hazards of monosodium glutamate. Compr Rev Food Sci Food Saf. 2019;18(4):1111-1134.
2. Eweka AO, Igbigbi PS, Ucheya RE. Histochemical studies of the effects of monosodium glutamate on the liver of adult wistar rats. Ann Med Health Sci Res. 2011;1(1):31-36.
3. Roberts A, Lynch B, Rietjens IMCM. Risk assessment paradigm for glutamate. Ann Nutr Metab. 2018;73(suppl 5):53-64.

4. Ghoshal S, Witta J, Zhong J, et al. Glutamic acid intake by formula-fed infants: are acceptable daily intakes appropriate? Eur J Pediatr. 2023;182(9):4215-4222.
5. Kasmara DP, Abdullah E, Harun Z, et al. Mini review of plant products as food supplement against MSG-induced liver injury: antioxidant, oxidative stress and histological prospects. Front Pharmacol. 2025;16:1522814.
6. Zanfirescu A, Ungurianu A, Tsatsakis AM, et al. A review of the alleged health hazards of monosodium glutamate. Compr Rev Food Sci Food Saf. 2019;18(4):1111-1134.
7. Moore KL. Congenital malformations due to environmental factors. In: Developing Humans. 2nd ed. Philadelphia: W.B. Saunders Co. Ltd; 2003. p. 173-183.
8. Allen GH. The genetic basis of diseases. In: General Pathology. New York: Churchill Livingstone Medical Division Longman; 1987. p. 35056.
9. Zerasky K. Nutrition and healthy eating; monosodium glutamate: Is it harmful? [Internet]. Mayo Clinic; [cited 2010 Dec 23]. Available from: mayoclinic.com
10. Okwuraiwe PE. The role of Food and Drug Administration and Control (FDA&C) in ensuring the safety of food and food ingredients: A symposium held at Sheraton Hotel, Lagos. 1992 Sep 1. p. 6-15.
11. Rogers PP, Blundell JE. Umani and appetite: Effects of monosodium glutamate on hunger and food intake in human subjects. Physiol Behav. 1990;48(6):801-804.
12. Iwase M, Yamamoto M, Iino K, Ichikawa K, Shinohara N, Yoshinari F. Obesity induced by neonatal monosodium glutamate treatment in spontaneously hypertensive rats: an animal model of multiple risk factors. Hypertens Res. 1998;43:62-68.
13. Gobatto CA, Mello MA, Souza CT, Ribeiro IA. The monosodium glutamate (MSG) obese rat as a model for the study of exercise in obesity. Res Commun Mol Pathol Pharmacol. 2002;2:116-128.
14. Belluardo M, Mudo G, Bindoni M. Effect of early destruction of the mouse arcuate nucleus by MSG on age dependent natural killer activity. Brain Res. 1990;534:225-333.
15. Onakewhor JUE, Oforofuo IAO, Singh SP. Chronic administration of monosodium glutamate induces oligozoospermia and glycogen accumulation in Wister rat testes. Afr J Reprod Health. 1998;2(2):190-197.
16. Oforofuo IAO, Onakewhor JUE, Idaewor PE. The effect of chronic administration of MSG on the histology of the adult Wister rat testes. Bios Res Commun. 1997;9(2):12-14.
17. Eweka AO, Adjene JO. Histological studies of the effects of monosodium glutamate on the medial geniculate body of adult Wistar rat. Electron J Biomed. 2007;2:9-13.
18. Samuels A. The toxicity/safety of MSG: A study in suppression of information. Account Res. 1999;6(4):259-310.
19. Gartner LP, Hiatt JL. Color Atlas of Histology. 3rd ed. New York: Lippincott Williams & Wilkins Publishers; 2000. p. 294-301.
20. Eweka AO, Om'Iniabohs FAE. Histological studies of the effects of monosodium glutamate on the small intestine of adult Wistar rat. Electron J Biomed. 2007;2:14-18.
21. Eweka AO, Om'Iniabohs FAE, Adjene JO. Histological studies of the effects of monosodium glutamate on the stomach of adult Wistar rats. Ann Biomed Sci. 2007;6:45-52.
22. Eweka AO, Om'Iniabohs FAE. Histological studies of the effects of monosodium glutamate on the liver of adult Wistar rats. Internet J Gastroenterol. 2008;6. Available from: http://www.ispub.com/journal/the_internet_journal_of_gastroenterology/
23. Singh I. Textbook of Human Histology with color atlas. 3rd ed. New Delhi: Jaypee Brothers Medical Publishers Ltd; 1997. p. 238-244.
24. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980;284:555-

556.
25. Farber JL, Chein KR, Mittnacht S. The pathogenesis of irreversible cell injury in ischemia. Am J Pathol. 1981;102:271-281.
26. Waters CM, Wakinshaw G, Moser B, Mitchell IJ. Death of neurons in the neonatal rodent globus pallidus occurs as a mechanism of apoptosis. Neuroscience. 1994;63:881-894.
27. Johnson CE. Effects of fluid imbalances. In: Conn MP, editor. Neurosciences in Medicine. New York: JB Lippincott Company; 1995. p. 187-189.

Cite this article Patel S et al., Monosodium Glutamate-Induced Hepatotoxicity: A Critical Review of Mechanisms, Methodological Limitations, and Therapeutic Interventions. Indian Journal of Health Care, Medical & Pharmacy Practice. 2025;6(1):164-172.